Evolus (EOLS) Cash from Financing Activities (2017 - 2026)
Evolus (EOLS) reported Cash from Financing Activities of $7.6 million for Q1 2026, up 567.14% on a YoY basis from $1.1 million in Q1 2025, and up 9794.81% quarter-over-quarter from $77000.0 in Q4 2025.
Evolus (EOLS) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Evolus has reported Cash from Financing Activities for 10 years, with the latest figure at $7.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 567.14% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $26.6 million (up 21872.73% YoY), and the FY2025 full-year result was $17.3 million, down 63.43% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $7.6 million, up from $77000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $45.7 million in Q1 2024, with the low at -$1.8 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $6.6 million across 5 years, with a median of -$849000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 109.3% — and 2024, when it surged 3661.78%.
- Evolus' Cash from Financing Activities stood at -$1.5 million in 2022, then surged by 1651.58% to $23.5 million in 2023, then sank by 105.58% to -$1.3 million in 2024, then surged by 105.86% to $77000.0 in 2025, then soared by 9794.81% to $7.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $7.6 million (Q1 2026), $77000.0 (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | 7.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.62 Mn |
| Mar 31, 2026 | 7.62 Mn |
| Dec 31, 2025 | 77,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | -1.77 Mn |
| Sep 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Dec 31, 2023 | 23.52 Mn |
| Dec 31, 2023 | 23.52 Mn |